ClinicalTrials.gg
Drug

Ferrosoferric Oxide clinical trials

Also written Ferumoxytol and Feraheme.

Includes 2 studies of Ferumoxides.

studies test it
79
open now
13
in phase 3
17
first study started
2004

How each study uses Ferrosoferric Oxide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Ferrosoferric Oxide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Aug 1996 · FERIDEX I.V. · NDA 020416 (FDA, Drugs@FDA; as ferumoxides)
European Union
15 Jun 2012 · Rienso · EMEA/H/C/002215 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ferumoxytol injection
4
Ferumoxytol infusion
3
IV iron
2

Brand

Feraheme
52

Development codes

Rienso
1

Other names

Ferumoxytol
62
Ferumoxytol Non-Stoichiometric Magnetite
15

Studies by the year they started

79 studies that test it; most in 2011 (7)

Studies that test Ferrosoferric Oxide, by start year
YearStudies
20042
20063
20082
20092
20105
20117
20124
20136
20146
20156
20163
20177
20186
20192
20205
20214
20221
20232
20241
20253
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
12
Phase 1
14
Phase 2
18
Phase 3
17
Phase 4
10
No phase
12

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 65

AMAG Pharmaceuticals, Inc. (13) · OHSU Knight Cancer Institute (13) · Stanford University (3) · Auerbach Hematology Oncology Associates P C (3) · University of Pennsylvania (3) · Brigham and Women's Hospital (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2)

Often tested with

Tested in the same studies.

Ferrous sulfate (3) · Gadolinium (3) · Temozolomide (1) · Gadofosveset trisodium (1) · Hydrogen Peroxide (1) · Saline Solution (1) · Sodium Chloride (1) · Ascorbic Acid (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test Ferrosoferric Oxide.

Studies

Open first, then newest update. How each study uses Ferrosoferric Oxide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 79

See all 79 studies that test Ferrosoferric Oxide →

Given beside what is tested · 5 — Ferrosoferric Oxide is usual care or a partner of the new treatment

Codes

What other systems call Ferrosoferric Oxide · ClinicalTrials.gg INT008874

  • MeSH (NLM) D052203Ferrosoferric OxideConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) XM0M87F357FERROSOFERRIC OXIDEConfirmed FDA, NLM
  • RxNorm 1310708One source FDA
  • NCI Thesaurus C38138Ferrosoferric OxideOne source FDA

Also registered as ferumoxytol (UNII R8DG7T2D3A) and ferumoxytol non-stoichiometric magnetite (UNII CLH5FT6412 · RxNorm 473387).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.